We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Allergan Again Pressures FDA On Restasis Generics

Law360, New York (August 10, 2017, 6:17 PM EDT) -- Allergan PLC is continuing its push to keep a generic version of the dry-eye blockbuster Restasis off the market by submitting at least its third citizen petition to the U.S. Food and Drug Administration arguing that the agency is letting companies use insufficient studies to prove bioequivalence.

The Aug. 4 petition states that the agency shouldn't approve any generic versions that rely on “in vitro or other nonclinical analyses" as opposed to "one or more appropriately designed clinical endpoint bioequivalence studies." Or put more simply, it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.